Phospholipids and insulin resistance in psychosis: A lipidomics study of twin pairs discordant for schizophrenia

Genome Medicine

Volumn 4, Issue 1, 2012, Pages

  Orešič, Matej ^a   Seppänen Laakso, Tuulikki ^a   Sun, Daqiang ^b   Tang, Jing ^a   Therman, Sebastian ^c   Viehman, Rachael ^b   Mustonen, Ulla ^c   van Erp, Theo G ^d   Hyötyläinen, Tuulia ^a   Thompson, Paul ^e   Toga, Arthur W ^e   Huttunen, Matti O ^c   Suvisaari, Jaana ^c   Kaprio, Jaakko ^c,f   Lönnqvist, Jouko ^c,g   Cannon, Tyrone D ^b  

^a VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF HELSINKI   (Finland)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; DIACYLGLYCEROL; LYSOPHOSPHATIDYLCHOLINE; MONOACYLGLYCEROL; PHOSPHATIDIC ACID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLSERINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GRAY MATTER; HUMAN; INSULIN RESISTANCE; LIPIDOMICS; MALE; MONOZYGOTIC TWINS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; SCHIZOPHRENIA; SERUM; SYNAPTIC TRANSMISSION; TIME OF FLIGHT MASS SPECTROMETRY; TRIACYLGLYCEROL BLOOD LEVEL; TWIN DISCORDANCE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 84858079314     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm300     Document Type: Article

References (50)

1. Keshavan MS, Tandon R, Boutros NN, Nasrallah HA. Schizophrenia, "just the facts": What we know in 2008: Part 3: Neurobiology. Schizoph Res 2008, 106:89-107.
2. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008, 63:801-808. 10.1016/j.biopsych.2007.09.024, 18005941.
3. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998, 30:193-208. 10.1016/S0920-9964(97)00151-5, 9589514.
4. Schwarz E, Prabakaran S, Whitfield P, Major H, Leweke FM, Koethe D, McKenna P, Bahn S. High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res 2008, 7:4266-4277. 10.1021/pr800188y, 18778095.
5. Smesny S, Milleit B, Nenadic I, Preul C, Kinder D, Lasch J, Willhardt I, Sauer H, Gaser C. Phospholipase A2 activity is associated with structural brain changes in schizophrenia. Neuroimage 2010, 52:1314-1327. 10.1016/j.neuroimage.2010.05.009, 20478385.
6. Pearce JM, Komoroski RA, Mrak RE. Phospholipid composition of postmortem schizophrenic brain by 31P NMR spectroscopy. Magn Reson Med 2009, 61:28-34. 10.1002/mrm.21820, 2610237, 19097198.
7. Horrobin DF. Schizophrenia as a prostaglandin deficiency disease. Lancet 1977, 1:936-937.
8. Oresic M, Hänninen VA, Vidal-Puig A. Lipidomics: a new window to biomedical frontiers. Trends Biotechnol 2008, 26:647-652. 10.1016/j.tibtech.2008.09.001, 18951641.
9. Cannon TD, Kaprio J, Lonnqvist J, Huttunen M, Koskenvuo M. The genetic epidemiology of schizophrenia in a Finnish twin cohort. A population-based modeling study. Arch Gen Psychiatry 1998, 55:67-74. 10.1001/archpsyc.55.1.67, 9435762.
10. Spitzer RL, Williams JB, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry 1992, 49:624-629. 10.1001/archpsyc.1992.01820080032005, 1637252.
11. American Psychiatric Association Diagnostic and Statistical Manual for Mental Disorders 1994, Washington, DC: American Psychiatric Association, 4, American Psychiatric Association.
12. Cannon TD, Hennah W, van Erp TG, Thompson PM, Lönnqvist J, Huttunen M, Gasperoni T, Tuulio-Henriksson A, Pirkola T, Toga AW, Kaprio J, Mazziotta J, Peltonen L. Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. Arch Gen Psychiatry 2005, 62:1205-1213. 10.1001/archpsyc.62.11.1205, 16275808.
13. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 1982, 39:784-788. 10.1001/archpsyc.1982.04290070020005, 7165477.
14. Andreasen NC, Olsen S. Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry 1982, 39:789-794. 10.1001/archpsyc.1982.04290070025006, 7165478.
15. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005, 162:441-449. 10.1176/appi.ajp.162.3.441, 15741458.
16. Cannon TD, Huttunen MO, Lönnqvist J, Tuulio-Henriksson A, Pirkola T, Glahn D, Finkelstein J, Hietanen M, Kaprio J, Koskenvuo M. The inheritance of neuropsychological dysfunction in twins discordant for schizophrenia. Am J Hum Genet 2000, 67:369-382. 10.1086/303006, 1287184, 10880296.
17. Surface Curve Protocol. , http://www.loni.ucla.edu/~esowell/edevel/new_sulcvar.html
18. Medial Lines Protocol. , http://www.loni.ucla.edu/~esowell/edevel/MedialLinesProtocol.htm
19. Pluskal T, Castillo S, Villar-Briones A, Oresic M. MZmine 2: Modular framework for processing, visualizing, and analyzing mass spectrometry-based molecular profile data. BMC Bioinformatics 2010, 11:395. 10.1186/1471-2105-11-395, 2918584, 20650010.
20. Nygren H, Seppanen-Laakso T, Castillo S, Hyotylainen T, Oresic M. Liquid chromatography-mass spectrometry (LC-MS)-based lipidomics for studies of body fluids and tissues. Methods Mol Biol 2011, 708:247-257. 10.1007/978-1-61737-985-7_15, 21207295.
21. The R Project for Statistical Computing. , http://www.r-project.org/
22. Kampstra P. Beanplot: a boxplot alternative for visual comparison of distributions. J Stat Soft 2008, 28:1-9.
23. Fraley C, Raftery AE. Model-based methods of classification: Using the mclust software in chemometrics. J Stat Soft 2007, 18:1-13.
24. Zito T, Wilbert N, Wiskott L, Berkes P. Modular Toolkit for Data Processing (MDP): a Python data processing framework. Front Neuroinform 2008, 2:8. 2628591, 19169361.
25. Castelo R, Roverato A. Reverse engineering molecular regulatory networks from microarray data with qp-graphs. J Comp Biol 2009, 16:213-227.
26. Brohee S, Faust K, Lima-Mendez G, Vanderstocken G, van Helden J. Network Analysis Tools: from biological networks to clusters and pathways. Nat Protoc 2008, 3:1616-1629. 10.1038/nprot.2008.100, 18802442.
27. Orešič M, Tang J, Seppänen-Laakso T, Mattila I, Saarni SE, Saarni SI, Lönnqvist J, Sysi-Aho M, Hyötyläinen T, Perälä J, Suvisaari J. Metabolome in schizophrenia and other psychotic disorders: a general population-based study. Genome Med 2011, 3:e19.
28. Suvisaari JM, Saarni SI, Perälä J, Suvisaari JV, Härkänen T, Lönnqvist J, Reunanen A. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 2007, 68:1045-1055. 10.4088/JCP.v68n0711, 17685741.
29. Kirkpatrick B, Miller BJ, Garcia-Rizo C, Fernandez-Egea E, Bernardo M. Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits?. Schizophr Bull 2012, 38:280-284. 10.1093/schbul/sbq058, 20558532.
30. Guest PC, Schwarz E, Krishnamurthy D, Harris LW, Leweke FM, Rothermundt M, van Beveren NJ, Spain M, Barnes A, Steiner J, Rahmoune H, Bahn S. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 2011, 36:1092-1096. 10.1016/j.psyneuen.2010.12.018, 21251762.
31. Guest PC, Wang L, Harris LW, Burling K, Levin Y, Ernst A, Wayland MT, Umrania Y, Herberth M, Koethe D, van Beveren JM, Rothermundt M, McAllister G, Leweke FM, Steiner J, Bahn S. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol Psychiatry 2010, 15:118-119. 10.1038/mp.2009.81, 20098438.
32. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 2007, 24:481-485.
33. Kotronen A, Velagapudi VR, Yetukuri L, Westerbacka J, Bergholm R, Ekroos K, Makkonen J, Taskinen M-R, Oresic M, Yki-Järvinen H. Saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. Diabetologia 2009, 52:684-690. 10.1007/s00125-009-1282-2, 19214471.
34. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KRR. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 2007, 12:934-945. 10.1038/sj.mp.4002000, 17440431.
35. Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:27-38.
36. Pietiläinen KH, Sysi-Aho M, Rissanen A, Seppänen-Laakso T, Yki-Järvinen H, Kaprio J, Oresic M. Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects-a monozygotic twin study. PLoS ONE 2007, 2:e218. 10.1371/journal.pone.0000218, 1789242, 17299598.
37. Lagarde M, Bernoud N, Brossard N, Lemaitre-Delaunay D, Thies F, Croset M, Lecerf J. Lysophosphatidylcholine as a preferred carrier form of docosahexaenoic acid to the brain. J Mol Neurosci 2001, 16:201-204. discussion 215-221, 10.1385/JMN:16:2-3:201, 11478375.
38. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE. Long-chain {omega}-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010, 67:146-154. 10.1001/archgenpsychiatry.2009.192, 20124114.
39. Oken RJ, Schulzer M. At issue: schizophrenia and rheumatoid arthritis: the negative association revisited. Schizophr Bull 1999, 25:625-638.
40. Fuchs B, Schiller J, Wagner U, Hantzschel H, Arnold K. The phosphatidylcholine/lysophosphatidylcholine ratio in human plasma is an indicator of the severity of rheumatoid arthritis: investigations by 31P NMR and MALDI-TOF MS. Clin Biochem 2005, 38:925-933. 10.1016/j.clinbiochem.2005.06.006, 16043165.
41. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Bernstein D, Yolken RH. Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry 2001, 58:1032-1037. 10.1001/archpsyc.58.11.1032, 11695949.
42. Torrey EF, Yolken RH. The schizophrenia-rheumatoid arthritis connection: infectious, immune, or both?. Brain Behav Immun 2001, 15:401-410. 10.1006/brbi.2001.0649, 11782106.
43. Takatera A, Takeuchi A, Saiki K, Morioka I, Yokoyama N, Matsuo M. Blood lysophosphatidylcholine (LPC) levels and characteristic molecular species in neonates: prolonged low blood LPC levels in very low birth weight infants. Pediatr Res 2007, 62:477-482. 10.1203/PDR.0b013e31814625ca, 17667851.
44. Drobnik W, Liebisch G, Audebert FX, Frohlich D, Gluck T, Vogel P, Rothe G, Schmitz G. Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients. J Lipid Res 2003, 44:754-761. 10.1194/jlr.M200401-JLR200, 12562829.
45. Yan JJ, Jung JS, Lee JE, Lee J, Huh SO, Kim HS, Jung KC, Cho JY, Nam JS, Suh HW, Kim YH, Song DK. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med 2004, 10:161-167. 10.1038/nm989, 14716308.
46. Lusis AJ. Atherosclerosis. Nature 2000, 407:233-241. 10.1038/35025203, 2826222, 11001066.
47. Yetukuri L, Söderlund S, Koivuniemi A, Seppänen-Laakso T, Niemelä PS, Hyvönen M, Taskinen MR, Vattulainen I, Jauhiainen M, Oresic M. Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol. J Lipid Res 2010, 51:2341-2351. 10.1194/jlr.M006494, 2903811, 20431113.
48. Suvisaari JM, Saarni SI, Perala J, Suvisaari JV, Harkanen T, Lonnqvist J, Reunanen A. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 2007, 68:1045-1055. 10.4088/JCP.v68n0711, 17685741.
49. Kubota M, Miyata J, Yoshida H, Hirao K, Fujiwara H, Kawada R, Fujimoto S, Tanaka Y, Sasamoto A, Sawamoto N, Fukuyama H, Murai T. Age-related cortical thinning in schizophrenia. Schizophr Res 2011, 125:21-29. 10.1016/j.schres.2010.10.004, 21036016.
50. Rund BR, Melle I, Friis S, Johannessen JO, Larsen TK, Midboe LJ, Opjordsmoen S, Simonsen E, Vaglum P, McGlashan T. The course of neurocognitive functioning in first-episode psychosis and its relation to premorbid adjustment, duration of untreated psychosis, and relapse. Schizophr Res 2007, 91:132-140. 10.1016/j.schres.2006.11.030, 17258891.